[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487915":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":23,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":23,"enrollmentInfo":60,"targetDuration":23,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":33,"whyStopped":23,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Barts & The London NHS Trust","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with underlying LVZs (≥30% of LVZs in the LA body)","EXPERIMENTAL","Study 1- Developing a methodology and technique for sequential CV assessment. Twenty patients.\n\nStudy 2- Assess the mechanistic importance of RDCV slowing sites in AF. Twenty patients.\n\nStudy 3- Assess the impact autonomic modulation has on CV dynamics and RDCV slowing sites. Twenty patients.\n\nStudy 4- GP site ablation and substrate modification guided by RDCV slowing sites whereby substrate ablation is limited to substrate with these electrical properties and the impact on freedom from AF\u002FAT during 12 months follow-up. Forty patients.\n\n. Study 5- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients.",[13],"Other: Substrate guided ablation",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients without underlying LVZs (\u003C30% of LVZs in the LA body)","Study 1- Mechanistic importance of GP site ablation. Twenty patients.\n\nStudy 2- GP site ablation in addition to PV isolation and the impact on freedom from AF\u002FAT during 12 months follow-up. Forty patients.\n\nStudy 3- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Substrate guided ablation","Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.",[9,15],null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Shohreh Honarbakhsh, MRCP, BSc, PhD","CONTACT","020 3765 8682","shohreh.honarbakhsh@nhs.net",[31],{"facility":32,"status":33,"city":34,"state":23,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Barts Heart Centre, Barts Health NHS trust","RECRUITING","London","EC1A 7BE","United Kingdom","UK",{"type":39,"coordinates":40},"Point",[41,42],-0.12574,51.50853,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":23,"phoneExt":23,"email":29},{"name":26,"role":47,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100487915","personalised-ablation-strategies-in-af-100487915",false,"NCT05633303","Personalised Ablation Strategies in AF","Developing Dynamic Substrate Targeted Personalised Treatment Strategies in AF.","PAS","Inclusion Criteria:\n\n* Patients undergoing catheter ablation for persistent AF (\\\u003C24 months AF duration and no previous left atrial ablation).\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Unwillingness to sign consent\n* Age \\\u003C18 years\n* Contraindications for catheter ablation procedure","ALL","18 Years",{"count":61,"type":62},160,"ESTIMATED","INTERVENTIONAL",[65],"NA","Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.",[68],"Atrium; Fibrillation",[70,71,72,73],"Atrial fibrillation","Autonomic remodelling","Conduction velocity","Novel ablation strategies","2026-05-05",{"date":76,"type":77},"2026-05-08","ACTUAL",{"date":79,"type":77},"2022-10-14",{"date":81,"type":62},"2027-10-10",{"name":5,"class":6},1]